Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma

Overview of attention for article published in Journal of Translational Medicine, May 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial

Article in ESMO Open (April 2024)

Metronomic Temozolomide (mTMZ) and Bevacizumab—The Safe and Effective Frontier for Treating Metastatic Neuroendocrine Tumors (NETs): A Single-Center Experience

Article in Cancers (December 2023)

Virus-associated neuroendocrine cancers: Pathogenesis and current therapeutics

Article in Pathology - Research and Practice (July 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.